11843252

Source:http://linkedlifedata.com/resource/pubmed/id/11843252

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0069717, umls-concept:C0205179, umls-concept:C0671970, umls-concept:C1527249, umls-concept:C2603343
pubmed:issue	12
pubmed:dateCreated	2002-2-14
pubmed:abstractText	Capecitabine and oxaliplatin are both active anticancer agents in the treatment of patients with advanced colorectal cancer (ACRC). The aim of this dose-finding trial was to determine the maximum-tolerated dose (MTD), the dose-limiting toxicities (DLTs) and the activity of the combination in patients with advanced colorectal cancer.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/9007735
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Deoxycytidine, http://linkedlifedata.com/resource/pubmed/chemical/Fluorouracil, http://linkedlifedata.com/resource/pubmed/chemical/Organoplatinum Compounds, http://linkedlifedata.com/resource/pubmed/chemical/capecitabine, http://linkedlifedata.com/resource/pubmed/chemical/oxaliplatin
pubmed:status	MEDLINE
pubmed:month	Dec
pubmed:issn	0923-7534
pubmed:author	pubmed-author:CarpiAA, pubmed-author:CherubiniRR, pubmed-author:CognettiFF, pubmed-author:CostanzoE DED, pubmed-author:GasperoniSS, pubmed-author:Gruppo Oncologico Italiano per la Ricerca Clinica (GOIRC) and Gruppo..., pubmed-author:MoscettiLL, pubmed-author:PaoloniF PFP, pubmed-author:SdroboliniAA, pubmed-author:ZeuliMM
pubmed:issnType	Print
pubmed:volume	12
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	1737-41
pubmed:dateRevised	2007-11-15
pubmed:meshHeading	pubmed-meshheading:11843252-Adenocarcinoma, pubmed-meshheading:11843252-Adult, pubmed-meshheading:11843252-Aged, pubmed-meshheading:11843252-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:11843252-Colorectal Neoplasms, pubmed-meshheading:11843252-Deoxycytidine, pubmed-meshheading:11843252-Diarrhea, pubmed-meshheading:11843252-Dose-Response Relationship, Drug, pubmed-meshheading:11843252-Drug Evaluation, pubmed-meshheading:11843252-Female, pubmed-meshheading:11843252-Fluorouracil, pubmed-meshheading:11843252-Humans, pubmed-meshheading:11843252-Male, pubmed-meshheading:11843252-Maximum Tolerated Dose, pubmed-meshheading:11843252-Middle Aged, pubmed-meshheading:11843252-Neoplasm Staging, pubmed-meshheading:11843252-Organoplatinum Compounds, pubmed-meshheading:11843252-Safety, pubmed-meshheading:11843252-Survival Rate
pubmed:year	2001
pubmed:articleTitle	Capecitabine and oxaliplatin in advanced colorectal cancer: a dose-finding study.
pubmed:affiliation	Department of Medical Oncology A, Regina Elena Cancer Institute, Rome, Italy. massimozeuli@tiscalinet.it
pubmed:publicationType	Journal Article, Clinical Trial, Research Support, Non-U.S. Gov't, Multicenter Study, Clinical Trial, Phase I